STADA's Executive Board manages the Company with the goal of sustainable added value in its own responsibility in consideration of the concerns of the shareholders, its employees and other groups connected to the Company. The members of the Executive Board are jointly responsible for corporate governance. The Executive Board runs the businesses in accordance with the legal requirements, the Articles of Incorporation, the rules of procedure and the schedule of responsibilities.
born October 19,1964
Peter Goldschmidt has 28 years’ experience and success in the pharmaceutical industry with Novartis Pharma. He worked in OTC, Generics and the innovative Pharma Business in Asia, Europe and the US in several different leadership functions. From 2013 through 2018, Peter Goldschmidt was President of Sandoz US and Head of North America. He served on the Board of Directors as Vice Chair of Association for Accessible Medicines (AAM), the generics and biosimilar industry association in the U.S. Prior to this, Head of Sandoz Central and Eastern Europe and member of the Global Sandoz Executive Committee.
While at Sandoz North America he led the organization through several years of growth in the US through its generic and biosimilar portfolio expansion. By building a strong diverse leadership team he creates and a culture where associates are purpose-driven, resilient, engaged and thrive in the face of challenges. Peter Goldschmidt’s focus is on driving growth by expanding the portfolio and having strong partnerships in production and commercial activities while ensuring superior customer relations, strong supply chain reliability, ultimately leading to increased market share.
A German national, he is a graduate in politics and economic geography – and hold a master’s degree in sociology – from the University of Muenster in Germany. He has completed post-graduate studies at the London Business School, UK, and at the Harvard Business School and Stanford Business School in the US.
born November 3, 1957
Since September 27, 2017
Chief Financial Officer at STADA Arzneimittel AG
2013 - 2017
Partner at Albrecht, Prock & Partners AG, Switzerland
2005 - 2012
|Chief Financial Officer of Actavis Group, Iceland|
|2002 - 2005||Chief Financial Officer at Famar S.A., Greece|
2001 - 2002
|Chief Financial Officer at Ardana Biosciences Ltd., United Kingdom|
|1994 - 2000||Chief Financial Officer at Ashanti Goldfields Corporation, Ghana|
|1986 - 1994||Division Manager und Investment Officer at International Finance Corporation, USA|
|1984 - 1986||Master of Business Administration, Stanford Business School, USA|
|1980 - 1984||Financial Analyst, Ford Motor Company, United Kingdom|
|1976 - 1980||Master’s degrees in History and International Relations, Cambridge University, United Kingdom|
born on April 2,1965
Since July 1, 2018
Chief Technical Officer (CTO) at STADA Arzneimittel AG
2015 - June 30, 2018
Head of Global Technical Operations (Solids and Special Technologies), Novartis & Member of the Sandoz Executive Committee acting as Global Head of Technical Operations
2014 - 2015
|Head of Technical Operations Europa & India, Sandoz-Novartis|
|2012 - 2014||Vice President of Americas and Consumer Care Operations, Merck & Co (MSD)|
|2011 - 2012||Associate Vice President Pharmaceutical Operations-Puerto Rico, |
Merck & Co (MSD)
|2007 - 2011||General Manager of Las Piedras, Puerto Rico|
|2003 - 2006||Plant Manager, Schering-Plough, Madrid, Spain|
|2001 - 2003||Quality Head & Technical Director, Schering-Plough, Madrid, Spain|
|1995 - 2001||Pharmaceutical & Analytical Development Manager & Technical Director, CEPA Schwarz Pharma|
|1990 - 1995||Production Manager, Institute Berna Biotech (Crucell Biotechnology)|
|Education||Doctorate program in Pharmacy, Complutense University of Madrid, Spain|
|MBA/ Project Management, Commerce Association and Education|
Master in Industrial Pharmacy, Complutense University of Madrid, Spain
|Executive Program, Harvard Business School and Wharton. University of Pennsylvania|
|Bachelors of Pharmacy at Complutense University of Madrid, Spain|
Details on the remuneration of the members of the Executive Board can be found in the Remuneration Report in the Corporate Governance section under “Executive Board remuneration”.